EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Complexation of drug and hapten-conjugated aptamer with universal hapten antibody for pancreatic cancer treatment

Sun Il Choi, Yu-Sun Lee, Yul Min Lee, Hyun Jung Kim, Won Jong Kim, Sungjin Jung, Ji Eun Im, Mi Rim Lee, Joon Ki Kim, A-Ra Jeon, Sang Myung Woo, Goo Taeg Oh und 3 weitere

Journal of Controlled Release · 2023

DOI: 10.1016/j.jconrel.2023.03.048 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Controlled Release, 2023. Verfasst von Sun Il Choi und 14 weiteren Autor:innen. Beteiligte Einrichtung: Research Institute, National Cancer Center, Goyang 10408, Republic of Korea; Henan Key Laboratory of Brain Targeted Bio-Nanomedicine, School of Life …. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Owing to a lack of reliable markers and therapeutic targets, pancreatic ductal adenocarcinoma (PDAC) remains the most lethal malignant tumor despite numerous therapeutic advances. In this study, we utilized cell-SELEX to isolate a DNA aptamer recognizing the natural conformation of the target on the cell surface. PAp7T8, an aptamer optimized by size and chemical modification, exhibited specific targeting to pancreatic cancer cells and orthotopic xenograft pancreatic tumors. To confer therapeutic functions to the aptamer, we adopted a drug-conjugated oligobody (DOligobody) strategy. Monomethyl auristatin E was used as a cytotoxic drug, digoxigenin acted as a hapten, and the humanized anti-digoxigenin antibody served as a universal carrier of the aptamer. The resulting PAp7T8-DOligobody showed extended in vivo half-life and markedly inhibited tumor growth in an orthotopic pancreatic cancer xenograft model without causing significant toxicity. Therefore, PAp7T8-DOligobody represents a promising novel therapeutic delivery platform for PDAC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsCarcinoma, Pancreatic DuctalHumansPharmaceutical PreparationsCell Line, TumorAntibodiesOligonucleotidesXenograft Model Antitumor Assays

Stichwörter der Autor:innen

AptamerDrug deliveryOligobodyPancreatic ductal adenocarcinomaTargeted therapy

Substanzen

Pharmaceutical PreparationsAntibodiesOligonucleotides

Autor:innen und Institutionen

  • Research Institute, National Cancer Center, Goyang 10408, Republic of Korea; Henan Key Laboratory of Brain Targeted Bio-Nanomedicine, School of Life Sciences & School of Pharmacy, Henan University, Kaifeng, Henan 475004…
  • Research Institute, National Cancer Center, Goyang 10408, Republic of Korea; Department of Biomedical Science, Graduate School, Kyung Hee University, Seoul 02447, Republic of Korea.
  • Research Institute, National Cancer Center, Goyang 10408, Republic of Korea; JP Bio A Co., Seongnam 13606, Republic of Korea.
  • Research Institute, National Cancer Center, Goyang 10408, Republic of Korea; Biopharmaceutical Chemistry Major, School of Applied Chemistry, Kookmin University, Seoul 02707, Republic of Korea.
  • Department of Chemistry, POSTECH-Catholic Biomedical Engineering Institute, Pohang University of Science and Technology, Pohang 37673, Republic of Korea; School of Interdisciplinary Bioscience and Bioengineering, Pohang…
  • School of Interdisciplinary Bioscience and Bioengineering, Pohang University of Science and Technology, Pohang 37673, Republic of Korea.

Zitieren

APA

Choi, S. I., Lee, Y. S., Lee, Y. M., Kim, H. J., Kim, W. J., Jung, S., Im, J. E., Lee, M. R., Kim, J. K., Jeon, A. R., Woo, S. M., Oh, G. T., Heo, K., Kim, Y. H., & Kim, I. H. (2023). Complexation of drug and hapten-conjugated aptamer with universal hapten antibody for pancreatic cancer treatment. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2023.03.048

Vancouver

Choi SI, Lee YS, Lee YM, Kim HJ, Kim WJ, Jung S, et al. Complexation of drug and hapten-conjugated aptamer with universal hapten antibody for pancreatic cancer treatment. Journal of Controlled Release. 2023. doi:10.1016/j.jconrel.2023.03.048

BibTeX
@article{Choi2023,
  author = {Choi, Sun Il and Lee, Yu-Sun and Lee, Yul Min and Kim, Hyun Jung and Kim, Won Jong and Jung, Sungjin and Im, Ji Eun and Lee, Mi Rim and Kim, Joon Ki and Jeon, A-Ra and Woo, Sang Myung and Oh, Goo Taeg and Heo, Kyun and Kim, Yun-Hee and Kim, In-Hoo},
  title = {Complexation of drug and hapten-conjugated aptamer with universal hapten antibody for pancreatic cancer treatment},
  journal = {Journal of Controlled Release},
  year = {2023},
  doi = {10.1016/j.jconrel.2023.03.048}
}
Kostenlos starten →